Author: Ioanna Papanikolaidi

InSyBio, a leading biotechnology company that has developed a suite of advanced AI tools for biomarker discovery in clinical and multi-omics data, has announced a strategic partnership with Syndesis Health, a leader in global real-world evidence. The partnership aims to leverage the clinical and genomic data on Syntium, Syndesis’ data platform of global healthcare data, to accelerate research and development in several therapeutic areas, including cardiovascular health, oncology, and rare diseases.

The importance of biomarkers

Biomarkers are body characteristics that can be measured, such as the biological molecules found in bodily fluids or tissues, including DNA, antibodies, proteins, or other smaller molecules. They are necessary to predict the effectiveness of drugs and patient outcomes; however, biomarker discovery is a very complex and costly process that often results in poor or inaccurate outcomes due to the use of disparate tools and datasets, and the high complexity of high-throughput -omics data.

InSyBio’s platform simplifies and accelerates the process of biomarker discovery by providing a single, highly accurate, and effective processing pipeline that uses machine learning to analyze biodata. Syntium’s longitudinal datasets, which include clinical, genomic, and other data, are ideal for applying InSyBio’s suite of tools in biomarker discovery. Combining Syntium data with InSyBio’s platform will create a unique opportunity for biopharma and diagnostic companies to uncover breakthrough discoveries with the potential to vastly improve global patient outcomes.

“Precision medicine is still in its infancy and many patients are misdiagnosed or do not get the most beneficial treatment for them. The wealth of Syntium’s data sets when harnessed by our automatic AI-driven technology holds the potential to upend the medical field practices, and highly impact overall healthcare quality at national and international levels. We are looking forward to working with the innovative team of Syndesis Health“, said Labros Digonis, InSyBio CEO.

“We are incredibly excited to embark on this partnership with InSyBio to enable biomarker discovery for cutting-edge healthcare innovation”, said Josh Sutton, Syndesis Health CEO. “Together we seek to raise the bar for global health research and innovation in service of patients worldwide.”

About Syndesis Health. Syndesis Health is the data and technology catalyst to a multi-continent network of healthcare and life sciences organizations. Its primary aim is to enhance global health outcomes and equity through its secure data platform, Syntium, and the Syndesis Health Network, a member community promoting research collaboration, information sharing, and access to common tools. Visit https://syndesis.com to learn more.

About InSyBio. InSyBio is an international pioneer biotechnology company revolutionizing the medical field through targeted biomarker discovery, highly accurate predictive analytics and the development of personalization tests for drugs. Its solutions provide the R&D departments of Pharma and Research Institutes with the means to meet their most challenging research and innovation goals. This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics and clinical data, thus reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals, and research centres allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and a decrease of at least 80% in overall time and cost. Visit http://www.insybio.com for more information.

An increasing number of pharma and academic labs are getting access to multi-omics and multi-modal datasets. However, their processing requires multiple tools, while network analytics and data visualization can become challenging considering the high dimensionality, complexity and the presence of mutual information among different omics technologies. Moreover, predictive analytics using multi-omics data suffers from the curse of dimensionality and its performance is highly affected by data missingness and class imbalance leading to reduced reproducibility and classification metrics. With previous versions of InSyBio Suite. we have simplified multi-omics analysis providing optimized pipelines for preprocessing omics data and network and machine learning methods for the identification of biomarkers and training and testing predicting models.

The newly introduced version (version 3.1) of InSyBio Suite:

• Αllows for the first time the reconstruction and analysis of multi-omics networks (InSyBio BioNets),
• Provides an interactive environment for network visualization allowing the user-friendly projection of differential expression results on networks and their customization to summarize additional information and characterisation of the nodes (InSyBio BioNets).
• Introduces the use of Adaptive Boosting for solving the class imbalance problem in predictive analytics for biomarker discovery by expanding the dataset with technical data samples newar the classification hyperplane (InSyBio Biomarkers).

InSyBio is offering a one-month free license to use InSyBio Suite. Request your free trial now by completing a simple form at: https://insybio.com/get-a-free-one-month-license-of-insybio-suite/

About InSyBio: InSyBio is an international pioneer biotechnology company revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery, highly-accurate predictive analytics and the development of personalization tests for drugs, nutraceuticals and nutrition products.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models).  This is done through a   sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and a decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition. For more News visit our InSyBio Blog.

Fitly Health has partnered with InSyBio to deliver life-changing outcomes for patients and employees with metabolic disorders who need to lose weight. Everyone has a unique metabolism and research now shows that our metabolic health is largely affected by diet-influenced changes to our gut microbiome. In other words, existing dietary interventions would be more effective in the long-term if practitioners and dietitians first understood the type of proverbial “fuel” that’s best suited for each individual patient. Namely their gut biomarkers. It’s like telling every vehicle owner they should go to the gas pump and fill their tank up with regular fuel vs mid-grade or premium, but the reality is that most of us require premium fuel. Foods that are diverse in micronutrients, phytonutrients, and fibers needed to rebuild and sustain a healthy gut environment and fuel-efficient body.

This is why Fitly Health & InSyBio have partnered to create the world’s first “Metabolic AI™” program that’s powered by gut microbiome analysis, predictive generative AI, precision nutrition tracking, and virtual coaching for patients diagnosed with metabolic syndrome, prediabetes, and Type 2 diabetes for starters. Patients will also be incentivized to with financial incentives and rewards for adherence and completion of the 12-month program.

Fitly Health, a Miami-based precision nutrition startup, is the brain-child of Anthony Ortiz, a serial inventor who also created SmartPlate (https://getsmartplate.com/food-tracker), the world’s smartest food tracker that has been featured in the likes of Forbes, Shark Tank, and Times of London. InSyBio (www.insybio.com) is a multi-awarded international pioneer biotechnology company expediting biomarker discovery and predictive analytics for precision medicine and nutrition applications.

“I believe the future of medicine, wellbeing, and longevity will largely depend upon the diversity and health of our gut. As a proven disruptor in precision medicine and nutrition through biomarker discovery, we couldn’t be more excited to partner with Labros, Kostas, and the illustrious team at InSyBio.” said Anthony Ortiz, CEO at Fitly Health.

“Our synergy with Fitly Health, and their unique product (SmartPlate), presents a unique opportunity for us to bring our technology into the service of precision nutrition to harness the power of AI and the gut microbiome. Precision medicine and nutrition is the enabler of better health for everyone. Efficient biomarker discovery and training of accurate outcome prediction models have been traditionally a bottleneck in precision medicine and nutrition, but our synergy with Fitly Health offers an innovative solution for this problem. We are looking forward to this exciting endeavour and we envisage a fruitful collaboration that will improve the health of millions of patients worldwide and allow technology to positively disrupt the way we eat”, stated Labros Digonis, CEO of InSyBio.

About InSyBio: InSyBio is an international pioneer biotechnology company revolutionizing the medical field, clinical trials and food/nutrition industries through targeted biomarker discovery, highly-accurate predictive analytics and the development of personalization tests for drugs, nutraceuticals and nutrition products.

Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research and innovation goals (such as robust biomarker discovery and accurate predictive models).  This is done through a   sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics data reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and a decrease of at least 80% in overall time and cost.

Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition. For more News visit our InSyBio Blog.